Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-04-19
2011-04-19
Bristol, Lynn (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S387300, C536S023530
Reexamination Certificate
active
07927817
ABSTRACT:
Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs.
REFERENCES:
patent: 4470925 (1984-09-01), Auditore-Hargreaves
patent: 5530101 (1996-06-01), Queen et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5908925 (1999-06-01), Cohen et al.
patent: 6254868 (2001-07-01), Leung et al.
patent: 7399594 (2008-07-01), Rother et al.
patent: 2002/0177170 (2002-11-01), Luo et al.
patent: 2003/0040606 (2003-02-01), Leung
patent: 2003/0109680 (2003-06-01), Wong et al.
patent: 2003/0190705 (2003-10-01), Wong et al.
patent: 0939127 (1999-09-01), None
patent: WO-97/49429 (1997-12-01), None
patent: WO-03002607 (2003-01-01), None
patent: WO-03025019 (2003-03-01), None
Chothia C.; J. Moi Biol., Aug. 1987; 196 (4): 901-17, “Canonical Structures For the Hypervariable Regions of Immunoglobulins”.
Couto, J. et al., “Anti-BA46 Monoclonal Antibody Mc3: Humanization Using a Novel Positional Consensus and in Vivo and in Vitro Characterization,” Cancer Res. 55:1717-1722, (Apr. 15, 1995).
Foote J., J. Moi Biol., Mar. 20, 1992; 224 (2) 487-99, “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops”.
Jones PT., Nature, May 29-Jun. 4, 1986; 321 (6069); 522-5, “Replacing ttie Complementaryity-Determining Regions in a Human Antibody With Those From a Mouse”.
Leung, S-O. et al., “Construction and Characterization of a Humanized, Internalizing, B-Cell (CD22)-Specific Leukemia/Lymphoma Antibody, LL2,” Mol. Immunol. 32(17/18): 1413-1427, (1995).
Ohtomo, T. et al. “Humanization of Mouse ONS-M21 Antibody with the aid of hybrid variable regions,” Mol. Immunol. 32(6): 407-416, (1995).
Radar, C. et al. “A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries,” Proc. Natl. Acad. Sci. USA 95: 8910-8915, (Jul. 1998).
Reichmann L. et al., Nature 1988, 332, 323-327, “Reshaping Human Antibodies for Therapy”.
Rosok et al., “A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab,” Journal of Biological Chemistry, 271(37):22611-22618, (1996).
Rosok MJ, J Biol. Chem.I Sep. 13, 1996; 271 (37) : 2211-8, “A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab.”
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. USA, 79:1979-1983, (1982).
Santos AD., Prog. Nucleic Acid Res. Moi Biol. 1998; 60:164-94, “Development of More Efficacious Antibody for Medical Therapy and Diagnosis”.
Sato K., Immunol., Apr. 1995; 31 (5):371-81, “Humanization of a Mouse Anti-Human Interleukin-6 Receptor Antibody Comparing Two Methods For Selecting Human Framework Regions”.
Takeda S., Nature, Apr. 4-10, 1985; 314 (6010):452-4, “Construction of Chimaeric Processed Immunoglobulin Genes Containing Mouse Variable and Human Constant Region Sequence”.
Volume 272, No. 16, Issue of Apr. 18, 1997, pp. 10678-10684, “Antibody Humanization Using Momoyalent Phage Display”.
Yelton et al., The Journal of Immunology 1995, pp. 1994-2004, “Affinity Maturation of the BR96 Anti-Carcinoma Antibody By Codo Based Mutagenesis”.
Harris et al., “Profiles for the Analysis of Immunoglobulin Sequences: Comparison of V Gene Subgroups,” Protein Science, vol. 4, pp. 306-310 (1995).
Qu et al., Humanization of Immun31, an α-Fetoprotein-specific Antibody. Clinical Cancer Research. vol. 5, No. 10 pp. 3095s-3100s, Oct. 1999.
“Construction and Characterization of a Humanized, Internalizing, B-Cell (CD22)-Specific, Leukemia/Lymphoma Antibody, LL2”, Leung et al., Molecular Immunology, vol. 31, pp. 17-18 (1995).
“Humanization of Innmu31, an a-Fetoprotein-specific Antibody”, Qu et al., Clinical Cancer Research, The American Association for Cancer Research, US, vol. 5, No. 10, pp. 3095S-3100S (1999).
Baca, M. et al., “Antibody Humanization Using Monovalent Phage Display,” J. Biol. Chem. 272(16): 10678-10684, (1997).
Benhar, I. et al., “Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38,” Proc. Natl. Acad. Sci. USA 91: 12051-12055, (Dec. 1994).
Rother Russell P.
Wu Dayang
Alexion Pharmaceuticals, Inc.
Bristol Lynn
Ropes & Gray LLP
LandOfFree
Hybrid antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hybrid antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybrid antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2717634